Archive for March 2020

Treatment with ticagrelor alone reduces adverse events in patients with diabetes

Reviewed by Emily Henderson, B.Sc.Mar 30 2020

Patients with diabetes who stopped taking aspirin three months after the insertion of a coronary stent and then took the anti-platelet medication ticagrelor alone for a year had fewer episodes of bleeding and no increase in heart attacks, stroke or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor for a year. The research was presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

In patients with diabetes, treatment with ticagrelor alone significantly reduced clinically relevant bleeding compared with ticagrelor plus aspirin, without increasing the risk for additional heart attacks, strokes or death."

Dominick J. Angiolillo, MD, PhD, professor of medicine at the University of Florida College of Medicine in Jacksonville, Florida and first author of the study

The present study was a planned analysis of the TWILIGHT trial, he added, the results of which were published in the New England Journal of Medicine in November 2019. "These findings are consistent with the overall results of the TWILIGHT trial and were seen across all types of diabetes patients, irrespective of their clinical presentation and the treatment they were receiving for their diabetes."

Most heart attacks and strokes are caused by a blood clot in an artery that's been narrowed by a buildup of fatty deposits or plaque. Blood cells known as platelets help the blood to clot, and both ticagrelor and aspirin stop platelets from forming a clot that can block blood flow. Aspirin, however, also heightens the risk of bleeding, particularly in the gastrointestinal tract. The TWILIGHT trial tested whether ticagrelor alone or ticagrelor plus aspirin more effectively reduced bleeding without increasing the risk for heart attacks, stroke, death or other adverse events caused by arterial blockages in patients who had received at least one stent and were at high risk for adverse events.

Stenting, also known as coronary angioplasty or percutaneous coronary intervention, is a minimally invasive procedure in which a flexible tube (catheter) is threaded through an artery under local anesthesia. At the site of the blockage, a tiny balloon at the tip of the catheter is inflated to unblock the artery and a stent, a tiny mesh tube coated with medication, is inserted to prop it open.

The TWILIGHT trial enrolled 9,006 patients at 187 medical centers in 11 countries, including the United States, Canada, the United Kingdom, India, Israel, China and five European countries, who had received at least one stent and were at high risk for bleeding or another arterial blockage. Results showed that ticagrelor alone reduced clinically relevant bleeding more than ticagrelor plus aspirin without increasing the risk of death, heart attack or stroke.

The current study looked just at the subgroup of randomly assigned patients in the TWILIGHT trial who had diabetes (2,620 patients or 37% of all the randomly assigned patients). In this subgroup, patients who received ticagrelor plus a placebo were less likely to have clinically significant bleeding compared with those who received ticagrelor plus aspirin, 4.5% vs. 6.7%, respectively.

On the secondary endpoint, 4.6% of the patients treated with ticagrelor plus a placebo died or had a heart attack or stroke, compared with 5.9% of those who received ticagrelor plus aspirin. Although this reduction was not statistically significant, it offered some reassurance that patients were not harmed by the elimination of aspirin, Angiolillo said.

"Our primary goal was to ensure that dropping aspirin would reduce bleeding without increasing deaths, heart attacks or strokes," he said. "That goal was met."

The findings have some limitations. Patients' treating physicians made the diagnosis of diabetes, which was not confirmed by laboratory testing. Also, patients with the most severe type of heart attack, known as an ST-elevation myocardial infarction (STEMI), were excluded from the trial, so the results do not apply to them. In a STEMI heart attack, an artery to the heart is generally completely blocked, causing the death of some heart tissue. The patients enrolled in TWILIGHT had had either a non-ST-elevation myocardial infarction (NSTEMI) heart attack, in which a sudden arterial blockage due to blood clots partially stops blood flow to the heart, or stable angina, in which blood flow to the heart is interrupted by chronic arterial blockages.

Further research is needed to identify the best treatment for patients like those treated in the TWILIGHT trial after they have completed a year on ticagrelor monotherapy, Angiolillo said.

"What should we do after one year? Should patients continue on a lower dose of ticagrelor?" he said. "This is currently an unanswered question."

This study was investigator initiated, but received funding from AstraZeneca, which manufactures ticagrelor.

This study was simultaneously published online in the Journal of the American College of Cardiology at the time of presentation.

Leave a comment

AstraZeneca scores win as diabetes drug shown to slow kidney disease

(Reuters) - AstraZeneca's diabetes treatment Farxiga has proven to be "overwhelmingly" effective at slowing chronic kidney disease ahead of the scheduled end of a drug trial, the British drugmaker said, potentially opening a new area of treatment outside diabetes.

An interim study analysis showed that patients on Farxiga, known as Forxiga outside North America, had better renal function and were less likely to die from heart of kidney disease than a control group on placebo, the company said on in a statement on Monday.

An independent monitoring committee stopped the trial early as it was no longer justifiable to keep patients on placebo.

Farxiga, among AstraZeneca's top five drugs by sales, was first developed as a diabetes drug as it causes the kidneys to expel blood sugar from the body through urine but it has shown promise as a heart failure treatment, even among non-diabetic patients.

"Farxiga is moving from diabetes into the larger and more attractive (cardiovascular)/metabolism field where it may distinguish itself more easily from the rest of the antidiabetics," said Eric Le Berrigaud, an analyst at brokerage Bryan Garnier.

Analysts on average expect the drug to generate $3 billion in sales in 2024, up from $1.5 billion last year.

The company said details of how well the drug did against chronic kidney disease would be presented at an as yet undisclosed medical conference. It will also start talking to regulators about an early request for market approval for the new use, Astra added.

Farxiga is part of the SGLT2-inhibitor class of antidiabetics which includes Eli Lilly and Boehringer Ingelheim's Jardiance as well as Johnson & Johnson's Invokana.

U.S. regulators this month granted fast track designation to Jardiance for the treatment of chronic kidney disease.

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Shounak Dasgupta and Louise Heavens)

Leave a comment

Diabetes Treatment Devices Market 2020 Size, Share, Growth Factor and Top Key Companies : F. Hoffmann-La Roche Ltd., Eli Lilly Company, BD and Others

Diabetes Treatment Devices Market 2020 Global Industry Size, Share, Growth Factor, Regional overview and Forecast Research Report 2026

This press release was orginally distributed by SBWire

Pune, India -- (SBWIRE) -- 03/20/2020 -- The Global Diabetes Treatment Devices Market to reach a value of US$ 16,706.4 Mn from US$ 10,826.6 Mn. The forecast period is set from 2018 to 2026, and the market is expected to grow at a CAGR of 5.6%. All information related to the market is provided in the report, titled," Diabetes Treatment Devices Market Size, Share and Global Trend by Product (Insulin Pens, Insulin Pumps, Insulin Jet Injectors, Insulin Syringes, Others), By Distribution Channel (Institutional Sales (Hospitals, Clinics), Retail Sales (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)) & Geography Forecast till 2026". The rising prevalence of diabetes on worldwide basis is the main factors propelling growth of the diabetes treatment devices market.

The report covers:

Global Diabetes Treatment Devices Market trends, with detailed analysis on consumer trends & manufacturer trends.Overview on supply analysis covering trends across raw material suppliers, technology providers and distributors.Key areas of investments identifying market opportunities and challenges in forecast timeframe.Competitive analysis of the industry players along with the overview on strategic management.Comprehensive company profiles of the major industry players.

Request a Sample Copy of the Diabetes Treatment Devices Market Research Report

Leading Players operating in the Diabetes Treatment Devices Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

Hoffmann-La Roche Ltd.MedtronicTandem Diabetes Care, Inc.BD, Eli LillyCompanySanofi

Asia Pacific to Emerge Dominant on Account of Mass Patient Pool

Fortune Business Insights foresees the global diabetes treatment devices market to be dominated by Asia Pacific. This is likely to remain the same in the forecast duration as well owing to the rising geriatric population and their susceptibility towards various diseases especially diabetes and heart problems. In 2018, Asia Pacific generated a revenue of US$ 4,334.8 Mn owing to the increasing adoption of advanced insulin device for treating diabetes.

The American Diabetes Association published an article stating 60% people in Asia Pacific live with diabetes out of which one-half is registered by China and India together. The huge patient pool for diabetes is a major factor promoting growth of the global diabetes treatment device market in the coming years.

Key Segmentation:

By Product

Insulin PensInsulin PumpsInsulin Jet InjectorsInsulin SyringesOthers

By Distribution Channel

Institutional SalesHospitalsClinics

Others

Retail SalesHospital PharmaciesRetail PharmaciesOnline Pharmacies

Rising healthcare Issues Related to Diabetes Encouraging People to Opt for Diabetic Treatment Equipment

As mentioned earlier, the rising prevalence of diabetic people around the world is a major driver for the diabetes treatment device market. This, coupled with advancement in technology and upgradation of existing devices used for diagnosing diabetes is also fueling its demand in the market. The rising healthcare expenditures for diabetes-related issues, especially in developing nations is propelling the demand for using diabetic equipment such as insulin pens and insulin pumps. This is further expected to drive the market in the coming years.

However, the market may face challenges, such as high cost of devices used for treating diabetes which may discourage people from opting these devices. In addition to that, the presence of traditional diabetes treatment methods such as regular allopathic medicines, restricted diet and others may also stop people from adopting the trial and testing methods of controlling diabetes. Furthermore, lack of reimbursement policies, especially in emerging nations may also hamper the market in the long run.

Have Any Query? Ask Our Experts

Report Focus:

Extensive product offeringsCustomer research servicesRobust research methodologyComprehensive reportsLatest technological developmentsValue chain analysisPotential Diabetes Treatment Devices Market opportunitiesGrowth dynamicsQuality assurancePost-sales supportRegular report updates

Reasons to Purchase this Report:

Comprehensive analysis of the Diabetes Treatment Devices Market growth drivers, obstacles, opportunities, and other related challenges.Tracks the developments, such as new product launches, agreements, mergers and acquisitions, geographical expansions, and joint ventures.Identifies market restraints and boosters.Identifies all the possible segments present in the market to aid organizations in strategic business planning.

More Trending Topics From Fortune Business Insights@

Medical Lasers Market to Reach US$ 12,327.8 Mn by 2026, OmniGuide's Attractive Product Portfolio Will Enable Market, says Fortune Business Insights

Surgical Stapling Devices Market Will Exhibit a CAGR of 7.4%; Rising Number of Surgical Procedures Will Create Lucrative opportunities, says Fortune Business Insights

U.S Secondary Hyperparathyroidism Treatment (SHPT) Market Size Worth USD 7.06 Billion by 2026; Increasing Launch of Effective Drugs Will Create Growth Opportunities

About Fortune Business Insights™Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune - 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email:sales@fortunebusinessinsights.com

Linkedin | Twitter | BLogs

For more information on this press release visit: http://www.sbwire.com/press-releases/diabetes-treatment-devices-market-2020-size-share-growth-factor-and-top-key-companies-f-hoffmann-la-roche-ltd-eli-lilly-company-bd-and-others-1282922.htm

Leave a comment

Diabetes Devices Market 2016: Dynamics, Segments and Supply Demand Forecast 2022

Mar 27, 2020 (AmericaNewsHour) -- The Global Diabetes Devices Market was valued at $18.5 billion in 2015 and is expected to grow at a CAGR of 5.93% to reach $30.25 billion by 2021. Glucose monitoring devices will be the largest growing category in the market with a CAGR of 6.02 % followed by insulin delivery devices forecasted to grow at a CAGR of 5.59 %. Diabetes is a metabolic disorder in which the pancreas ability to produce or use insulin is affected and hence blood glucose levels rises than the normal level of glucose. Diabetes devices are used for monitoring and management of the level of glucose in a diabetic patient's body. These devices also facilitate the delivery of insulin in the patient's body.

Download Sample of This Strategic Report: https://www.kennethresearch.com/sample-request-10064923

Market Dynamics:The Diabetes Market is driven by large diabetic patient pool caused by rapid urbanization and sedentary lifestyle. In addition, factors such as more R&D in diabetes diagnosis, technological advancements in the field of diabetes devices and a demand for faster and safer diagnosis & treatment of diabetes are adding to growth. The growing demand for minimally or non-invasive products is expected to propel the market growth further.There are certain restraints in the market such as high cost associated with the diagnosis and treatment, irregular reimbursement and patent expiry. In addition, certain devices don't give an exact figure but a range in which a certain parameter may lie, for example, blood glucose monitoring devices give a range about the blood glucose level of a patient.

Market Segmentation:The market is segmented intoGlucose Monitoring Devices MarketBlood glucose metersTesting stripsBlood glucose testing stripsContinuous glucose monitoring deviceLancetsInsulin Delivery Devices Market GlucoseInsulin syringesInsulin pumpsInsulin pensInsulin injectors

Geographic Analysis:North America has the largest market share of around 32% in 2015 and is expected to grow at a CAGR of 5.9%. The US is the major revenue pocket in this region. In 2015, Europe was the second largest market followed by Asia-Pacific. Asia-Pacific will be the fastest growing segment in this market especially countries like China and India owing to the high prevalence of diabetes, growing disposable income, rising awareness regarding these devices among others.Download Sample of This Strategic Report: https://www.kennethresearch.com/sample-request-10064923

Key Companies:The key players profiled in this market are Abbott Laboratories, Dexcom Inc., ACON Laboratories Inc., Becton, Dickinson and Company, Johnson & Johnson, Dexcom Inc., F. Hoffmann-La Roche Ltd, Medtronic plc and Terumo Corporation.

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth ResearchEmail:Sales@kennethresearch.comPhone:+1 313 462 0609

The post Diabetes Devices Market 2016: Dynamics, Segments and Supply Demand Forecast 2022 appeared first on America News Hour.

COMTEX_363890118/2606/2020-03-27T05:37:59

Leave a comment

Maintaining VDR levels in pancreatic cells could protect against diabetes

Maintaining vitamin D receptor (VDR) levels in pancreatic cells that synthesize and secrete insulin (β cells) could contribute to protecting against the development of diabetes and counteract pancreatic cell damage caused by the progression of the disease. This is suggested by a study conducted by researchers of the CIBER's area of Diabetes and Associated Metabolic Diseases (CIBERDEM) at the Universitat Autònoma de Barcelona (UAB), which points to this receptor as a potential therapeutic target in the prevention and treatment of the disease.

Vitamin D deficiency has been associated with a greater prevalence of both type 1 (T1D) and type 2 (T2D) diabetes, and the relation of this disease with variations in the vitamin D receptor gene has also been described. Nevertheless, the specific participation of this vitamin receptor in the development of the disease, specifically in the β cells, continues to be unknown. That is why this new study has focused its efforts on understanding the role played by the VDR of these pancreatic cells in the development of diabetes, by analyzing its behavior in mice.

Decreased VDR expression in diabetics

Researchers observed lower VDR expression in the pancreatic islets of mice with both type 1 and type 2 diabetes. In addition, they also demonstrated that the overexpression of VDR in β cells of diabetic mice counteracted the disease, while at the same time proving that sustained levels of vitamin D receptors in these cells could preserve their mass and function and protect against diabetes.

These results suggest that maintaining VDR expression could be essential in counteracting damage to β cells and protect against the development of the disease.

Sustained VDR levels protected transgenic mice from developing severe hyperglycemia, partially preserving the mass of β cells, thereby reducing local inflammation and diabetes. All of this reveals an unprecedented role of the vitamin D receptor in the pathophysiology of diabetes".

Alba Casellas, CIBERDEM researcher at the Centre for Animal Biotechnology and Gene Therapy (CBATEG) at the Universitat Autònoma de Barcelona and coordinator of the study

Glucose stimulates the vitamin D receptor

The researchers also confirmed that VDR expression was negatively correlated with circulating sugar levels, i.e., glucose stimulates VDR: "Unexpectedly, we demonstrated that the vitamin D receptor decreases when circulating glucose levels are physiologically low, such as after fasting". In relating this to the characteristics of pancreatic cells in diabetic individuals, what stood out was that "these results could be explained due to the fact that diabetes is associated with low intracellular glucose levels".

Usefulness of vitamin D in treating diabetes

Although the benefits of supplementing with vitamin D as a way to prevent diabetes have been widely reported, clinical data on its effectiveness in improving the state of diabetes are controversial. "Discrepancies in the effectiveness of vitamin D supplements can be due to the negative regulation of the VDR during diabetes", Dr. Casellas points out in view of these results.

Therefore, the authors suggest that to achieve positive results, the dosage regimen of vitamin D supplementation must be scheduled in the absence of VDR expression decrease. "Therefore, future strategies for the treatment of diabetes should be based on better knowledge of the mechanisms subjacent to the negative regulation of VDR during diabetes and focus on restoring VDR levels", they conclude.

The research, which was conducted by the CIBERDEM group led by Fàtima Bosch at the Centre for Animal Biotechnology and Gene Therapy of the Universitat Autònoma de Barcelona, was published in Diabetes, the official journal of the American Diabetes Association (ADA), and will be the object of a commentary in May's "In This Issue of Diabetes" section.

Source:

Journal reference:

Morró, M., et al. (2020) Vitamin D Receptor overexpression in β-cells ameliorates diabetes in mice. Diabetes. doi.org/10.2337/db19-0757.

Leave a comment

Many older adults receive inpatient diabetes treatment intensification

(HealthDay)—One in 10 older adults hospitalized for common medical conditions are discharged with intensified diabetes medications, despite the fact that nearly half are unlikely to benefit from the intensification, according to a study published online March 24 in JAMA Network Open.

Timothy S. Anderson, M.D., from Beth Israel Deaconess Medical Center in Boston, and colleagues assessed how often hospitalized older adults are discharged with intensified diabetes medications and the likelihood of benefit associated with these intensifications. The analysis included 16,178 patients (aged ≥65 years; 98 percent men) with diabetes not previously requiring insulin who were hospitalized in a Veterans Health Administration hospital for common medical conditions (2012 to 2013).

The researchers found that 10 percent of patients were discharged with intensified diabetes medications, including 5 percent with new insulins and 3 percent with intensified sulfonylureas. However, nearly half of patients receiving intensification (49 percent) were unlikely to benefit due to limited life expectancy or already being at their goal hemoglobin A1c (HbA1c). One in five were expected to have potential benefit from intensification. Discharge with intensified diabetes medications was associated with both preadmission HbA1c level and inpatient blood glucose recordings. The predicted probability of receiving an intensification was 4 percent among patients with a preadmission HbA1c level <7 percent, without elevated inpatient blood glucose levels, and 21 percent for patients with severely elevated inpatient blood glucose levels.

"During hospitalization, consideration of long-term diabetes control is needed in addition to inpatient blood glucose recordings to reduce potentially nonbeneficial medication changes when older adults are discharged home," the authors write.

Copyright © 2020 HealthDay. All rights reserved.

Citation: Many older adults receive inpatient diabetes treatment intensification (2020, March 25) retrieved 27 March 2020 from https://medicalxpress.com/news/2020-03-older-adults-inpatient-diabetes-treatment.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Leave a comment

New therapeutic strategy against diabetes: Vitamin D

Maintaining vitamin D receptor (VDR) levels in pancreatic cells that synthesize and secrete insulin (β cells) could contribute to protecting against the development of diabetes and counteract pancreatic cell damage caused by the progression of the disease. This is suggested by a study conducted by researchers of the CIBER's area of Diabetes and Associated Metabolic Diseases (CIBERDEM) at the Universitat Autònoma de Barcelona (UAB), which points to this receptor as a potential therapeutic target in the prevention and treatment of the disease.

Vitamin D deficiency has been associated with a greater prevalence of both type 1 (T1D) and type 2 (T2D) diabetes, and the relation of this disease with variations in the vitamin D receptor gene has also been described. Nevertheless, the specific participation of this vitamin receptor in the development of the disease, specifically in the β cells, continues to be unknown. That is why this new study has focused its efforts on understanding the role played by the VDR of these pancreatic cells in the development of diabetes, by analyzing its behavior in mice.

Decreased VDR Expression in Diabetics

Researchers observed lower VDR expression in the pancreatic islets of mice with both type 1 and type 2 diabetes. In addition, they also demonstrated that the overexpression of VDR in β cells of diabetic mice counteracted the disease, while at the same time proving that sustained levels of vitamin D receptors in these cells could preserve their mass and function and protect against diabetes.

These results suggest that maintaining VDR expression could be essential in counteracting damage to β cells and protect against the development of the disease. "Sustained VDR levels protected transgenic mice from developing severe hyperglycemia, partially preserving the mass of β cells, thereby reducing local inflammation and diabetes," explains Alba Casellas, CIBERDEM researcher at the Centre for Animal Biotechnology and Gene Therapy (CBATEG) at the Universitat Autònoma de Barcelona and coordinator of the study. She goes on to say that, "all of this reveals an unprecedented role of the vitamin D receptor in the pathophysiology of diabetes."

Glucose Stimulates the Vitamin D Receptor

The researchers also confirmed that VDR expression was negatively correlated with circulating sugar levels, i.e., glucose stimulates VDR: "Unexpectedly, we demonstrated that the vitamin D receptor decreases when circulating glucose levels are physiologically low, such as after fasting." In relating this to the characteristics of pancreatic cells in diabetic individuals, what stood out was that "these results could be explained due to the fact that diabetes is associated with low intracellular glucose levels."

Usefulness of Vitamin D in Treating Diabetes

Although the benefits of supplementing with vitamin D as a way to prevent diabetes have been widely reported, clinical data on its effectiveness in improving the state of diabetes are controversial. "Discrepancies in the effectiveness of vitamin D supplements can be due to the negative regulation of the VDR during diabetes," Dr. Casellas points out in view of these results.

Therefore, the authors suggest that to achieve positive results, the dosage regimen of vitamin D supplementation must be scheduled in the absence of VDR expression decrease. "Therefore, future strategies for the treatment of diabetes should be based on better knowledge of the mechanisms subjacent to the negative regulation of VDR during diabetes and focus on restoring VDR levels," they conclude.

More information: Meritxell Morró et al, Vitamin D Receptor overexpression in β-cells ameliorates diabetes in mice, Diabetes (2020). DOI: 10.2337/db19-0757

Citation: New therapeutic strategy against diabetes: Vitamin D (2020, March 27) retrieved 27 March 2020 from https://medicalxpress.com/news/2020-03-therapeutic-strategy-diabetes-vitamin-d.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Leave a comment

Regenacy Pharma snags $30M for diabetic neuropathy treatment

Treatments for diabetic peripheral neuropathy—nerve damage stemming from diabetes—tend to focus on managing pain. But Regenacy Pharmaceuticals' approach aims to reverse the nerve damage that causes that pain, and the company has scored $30 million to push its program into phase 2.

People with diabetes may develop peripheral neuropathy over time as high levels of sugars and fats in the blood damage their nerves. Patients feel pain most commonly in the fingers, arms, legs and feet and may eventually lose feeling in those areas, which can lead to serious infections. Addressing diabetes is a major part of treating diabetic neuropathy, but there is no treatment that reverses nerve damage.

RELATED: Neurogene nets $68.5M to advance gene therapies for rare neurological diseases

Regenacy's treatment, ricolinostat, is a pill that inhibits histone deacetylase 6 (HDAC6). Blocking this enzyme restores the function of microtubules, known as the "railways" cells use to transport energy and nutrients. A disease like diabetes or neurotoxic drugs used in chemotherapy can disrupt this transport, causing nerve damage.

"We are fortunate to have the strong support of investors aligned with our mission to provide lasting relief of all symptoms of diabetic peripheral neuropathy," Regenacy CEO Simon Jones, Ph.D., said in a statement. "Our preclinical studies demonstrate that selectively inhibiting HDAC6 has the potential to safely restore nerve function in multiple peripheral neuropathies, and we are looking forward to advancing our lead program into phase 2 studies this year."

RELATED: Peripheral neuropathy could be reversed by FDA-approved class of drugs

Cobro Ventures and Taiwania Capital Management led the series A round, with 3E Bioventures Capital, Yonjin Capital, Viva Biotech Holdings and Ta Ya Venture Holdings also chipping in.

"Regenacy is diligently working on developing a therapeutic that addresses the underlying causes of peripheral neuropathy," Marc Cohen, Regenacy's executive chairman and co-founder of Cobro Ventures, said. "We believe the company's HDAC6 approach has a strong potential to provide long-term improvements in pain, motor function and sensitivity in patients with this disease."

Leave a comment

Novel Therapies for Treatment of Diabetes Patents for Sale on the Ocean Tomo Bid-Ask™ Market

Ocean Tomo Bid-Ask™ Market patent auction lot 108 consists of 10 US patents. The inventions disclose pharmaceutical compositions and methods for insulin independence through restoring and maintaining beta cells utilizing a new optimized hamster Reg3 gamma peptide.

CHICAGO, March 24, 2020 /PRNewswire-PRWeb/ -- Ocean Tomo Transactions, LLC will auction a portfolio of 10 US patents covering novel therapies for the treatment of diabetes. The patents in lot 108 disclose an invention that increases pancreatic beta cells and protects them through a generalized immune tolerance agent, such as cyclosporine. Even though new therapies are available to treat type 2 patients and numerous insulin preparations are available to treat both type 1 and 2 diabetes, none address the underlying cause of diabetes: too few beta cells. The patents in auction lot 108 disclose the use and efficacy of shorter bioactive Reg peptides to transform progenitor cells within the pancreas into new islets that generate new beta cells that produce insulin.

By combining an immune tolerance agent with shorter bioactive Reg peptides, the potential now exists to address the underlying cause of diabetes, which neither insulin nor any current diabetes therapies on the market address. In the US, the number of people diagnosed with diabetes is projected to increase to nearly 42 million by 2030. Projected diabetes‐related medical costs are likewise exp ected to increase to $472.0 billion by 2030.

The patents in this lot were issued from 2014 to 2016. They will expire from 2032 to 2034.

You can view the patents in Ocean Tomo Bid-Ask™ Market auction lot 108 here. To request bidder credentials or for f urther information on this auction or other auctions on the Ocean Tomo Bid-Ask™ Market, contact Layna Guo at Layna@OTI.com or 1-312-327-8179.

About the Ocean Tomo Bid-Ask™ Market

The Ocean Tomo Bid-Ask Market is an open on-line platform to buy and sell patents. This market is an important step forward, both as a simplified solution for patent transactions as well as a source of information on patent pricing. The Ocean Tomo Bid-Ask Market uniquely combines the efficiency of an online platform with an experienced team of brokers fluent in both English and Mandarin. The market uses standard transaction documents and is open, transparent and free to view.

 

SOURCE Ocean Tomo

Leave a comment

The only cure for COVID-19 "treatments" on social media is a healthy dose of skepticism.

Photo by Anilakkus @iStock

Unfortunately, ''remedies" for the COVID-19 pandemic are plentiful and easy to find online. In reality, there is (as yet) no cure or vaccine for the condition. But you wouldn't guess that by looking at social media.

One popular post advises drinking water every few minutes to ''flush out" the virus, while another oft-shared suggestion involves blasting hot air from your blow dryer up your nose, alternating the blasts with mists of water.

But that's just a start. The ideas are endless and conflicting, and those who post them often dig in their heels when the advice is challenged as irresponsible and without merit.

Real versus fake news

Ferreting out the valid information from the bogus can be difficult, made more so while our global population is anxious and stressed in this era of social isolation and lockdowns. But even with false information about Coronavirus at epidemic levels, we're here to help you stay smart, safe, and sane.

Everyone needs good information about COVID-19 prevention, but experts studying the virus and the outcome say this applies especially to those with an underlying condition—and that includes diabetes. Those with diabetes (as well as other chronic conditions) have a higher than average risk of developing complications and getting very sick if they get infected.

What possesses people to post the outlandish information on social media, often not credited to anyone more reputable than my sister's friend's friend?

"I think people are desperately looking to gain a sense of control,'' says Jessy Warner-Cohen, PhD, MPH, a senior psychologist at Northwell Health, in Lake Success, NY. And that perception of control may matter less to them than whether the information they spread is correct or not, she says.

"We have to recognize that a higher level of anxiety is the general state of affairs at the moment. When that happens, reactions may not be typical. People are looking at ways to make sense of something that doesn't make sense."

False information is dangerous in a pandemic

"In the beginning of the epidemic, people were talking about having Coronavirus parties to get it, similar to the idea of chicken pox parties before the vaccine was available," Warner-Cohen says. "That idea has fortunately died out."

But unfounded ideas still float around. One of the most outlandish and dangerous is the aforementioned YouTube video suggesting that people blast hot air from a hair dryer up their nose. The premise is that the virus can't live in a high-temperature environment. The claim has been roundly dismissed by the World Health Organization and others and criticized as being not only false but dangerous. Yet, it continues to be shared by well-meaning social media users.

Other memes and posts suggest drinking water frequently (always good to stay hydrated, but water won't kill the virus), using an ultraviolet disinfection lamp to sterilize the hands, spraying alcohol all over your body, rinsing your nose with saline, taking a very hot bath, eating garlic, and taking antibiotics (they work against bacteria, not viruses).

The World Health Organization (WHO) calls the avalanche of bad advice an "infodemic"

As the sketchy and dangerous information has proliferated, the World Health Organization is fighting back.  On its website, the WHO offers advice for the public in a mythbusters document, addressing some of the commonly circulating suggestions about curing the COVID-19 virus.

Centers for Disease Control (CDC) addresses the spread of misinformation

Likewise, the CDC has posted extensive information on its webpage, including facts to dispel rumors and advice about how to follow the agreed upon prevention measures known to be effective—such as social distancing and hand washing.

The site also has information on cases nationwide, how to prepare your house in case you need to quarantine yourselves, and how to cope with school closures, among other details.

Social media companies step up to combat fake news about COVID-19

As the questionable sources of information continue and grow, Twitter recently posted news about expanding its safety rules, tweeting:

"Update: we're expanding our safety rules to include content that could place people at a higher risk of transmitting COVID-19. Now, we will require people to remove Tweets that include the following content that increases the chance that someone contracts or transmits the virus, including:

  • Denial of expert guidance
  • Encouragement to use fake or ineffective treatments, preventions, and diagnostic techniques
  • Misleading content purporting to be from experts or authorities"
  • Likewise, Facebook also recently responded to the problem, posting a lengthy overview  about how it aims to keep people safe and informed about the Coronavirus. Among the measures are their goal of removing false information and conspiracy theories flagged by health experts as inaccurate or dangerous.

    Who to trust?

    For a satisfying and reliable takedown of websites that favor conspiracy theories—no, the virus was not manmade in a Chinese lab—and other misinformation, check out Stat News, a respected site that recently called out some of the more outlandish and dangerous COVID-19 posts.

    Health experts also recommend checking the websites of county and city departments of public health to stay up to date on what is happening in your area. Some local health departments live stream updates on Facebook.

    Listen to the authorities, tune out the imposters

    Warner-Cohen suggests focusing on the consistent messaging from organizations such as the WHO and the CDC. "There is a strong consensus of what we should be doing right now," she says, referring to the basic and widespread advice to stay home, avoid others, and practice good hygiene such as frequent handwashing. ''Also take social media breaks and news breaks," she says. 

    As for how to respond to those posts and memes that you know are false information? She suggests posting something like, ''There is no scientific basis for this," in the comments.

    Updated on: 03/24/20

    Dietary Supplements: Time to Consider What You're Really Taking

    Leave a comment

    Dario Diabetes Management Is Recognized as a Leading Application for Children/Young People Self-managing Healthcare During COVID-19 Pandemic

    NEW YORK, March 25, 2020 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a global digital therapeutics (DTx) innovator, announced today an endorsement from the U.K. based ORCHA, highlighting the Company's Diabetes Management Application as being suitable and safe for children and young people. In its recommendation, ORCHA mentioned the value of Dario's app in helping parents monitoring their child's diabetes information. The ORCHA team is part of NHS England's National Innovation Accelerator program and supports many NHS and local government organizations to drive the uptake of digital health among their populations.

    "This recognition from ORCHA further validates the use of our platform technology for remote patient monitoring for chronic care management, especially in these challenging times," said Erez Raphael, CEO of DarioHealth. "The ongoing COVID-19 pandemic has made it difficult for millions of patients worldwide with chronic disease to access healthcare though conventional channels. Our technology provides patients with easy to use software, testing supplies and personalized coaching around each user's data, enabling them to manage their disease without leaving the safety of their home."

    Base on ORCHA's criteria for evaluating smartphone technologies, the organization has included Dario Diabetes Management on a list of "Coronavirus" apps eligible for recognition, based on the following attributes:

  • Managing mental health, including anxiety,
  • Wellbeing,
  • Conditions such as asthma and diabetes.
  • ORCHA highlighted the value of healthcare apps in keeping children and young people engaged with their health and wellbeing, as well as relieving pressure on the NHS.

    ORCHA is the World's leading health app evaluation and advisor organization. It helps governments, health and social care organizations to choose and deliver health apps that will safely make the biggest impact in terms of improving outcomes. ORCHA's tools help health professionals to prescribe and monitor usage of health apps. They are proven to increase take-up and self-management of conditions.  

    About DarioHealth Corp.

    DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel.

    For more information, visit http://mydario.investorroom.com/.

    Cautionary Note Regarding Forward-Looking Statements

    This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, Dario is using forward-looking statements in this press release when it discusses the benefits of Dario's technology to patients. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Comp any's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new in formation, future events or otherwise, except as required by applicable law.

    Logo - http://mma.prnewswire.com/media/544126/DarioHealth_Logo.jpg

    DarioHealth Corporate Contact: 

    Claudia Levi  Content & Communications Manager[email protected] +1-347-767-4220

    Media Inquiries:

    Investor Relations Contact:Matthew Picciano[email protected] +1-646-889-1200

    SOURCE DarioHealth Corp.

    Related Links

    https://www.dariohealth.com

    Leave a comment

    Why Is Heart Disease a Complication of Type 2 Diabetes?

    Many people are aware of the strong link between type 2 diabetes and heart disease. Maybe you have one or both conditions, or know someone who does.

    It's important to know about this link if you have diabetes.

    Adults with diabetes are two to four times more likely to die from heart disease than those without diabetes. But there are ways to lower your risk.

    When multiple risk factors for type 2 diabetes and heart disease occur in the same person, it's called metabolic syndrome.

    Read on to learn more about the connection between these conditions — and some of the steps you can take to manage the risk.

    Metabolic syndrome occurs when someone has multiple risk factors for type 2 diabetes and heart disease. It includes having three or more of the following:

  • High blood sugar. High blood sugar occurs when your body doesn't have enough insulin or doesn't use insulin properly. When your body doesn't use insulin properly, it's known as insulin resistance.
  • High blood pressure. When your blood pressure is high, your heart has to work harder to pump blood around your body. This puts strain on your heart and can damage your blood vessels.
  • High triglyceride levels. Triglycerides are a form of fat that provide a stored source of energy for your body. When triglycerides levels are high, it can cause plaque to build up in your arteries.
  • Low HDL (good) cholesterol. HDL helps clear out LDL (bad) cholesterol from your blood vessels.
  • Excess belly fat. Carrying too much fat in your abdomen is linked to increased risk of insulin resistance, high blood sugar, high blood pressure, high triglycerides, and low HDL.
  • People with type 2 diabetes have insulin resistance, which stops their body from using sugar properly. This leads to high blood sugar.

    Insulin resistance and high blood sugar can affect your heart, blood vessels, and fat levels in several ways. This can raise your risk for heart disease.

    Over time, high blood sugar levels can cause damage to your body. Your heart and blood vessels are some of the areas that can be affected.

    For example, high blood sugar can:

  • Create more work for your heart. When there's a high amount of sugar in your blood, it takes more work for your heart to pump it.
  • Increase inflammation in your blood vessels. Inflammation in your arteries results in increased cholesterol buildup and artery hardening.
  • Damage small nerves in your heart. Nerve damage in your heart disrupts normal blood flow.
  • According to the American Diabetes Association, 2 out of 3 people with diabetes also have high blood pressure or take medication to reduce their blood pressure.

    Insulin resistance in people with type 2 diabetes may help explain why.

    Insulin resistance can narrow your blood vessels, making your blood pressure higher. It can also cause your body to hold on to salt, which can raise blood pressure as well.

    Insulin resistance and high blood pressure can both damage blood vessels, creating more work for your heart.

    Insulin resistance and high blood sugar can contribute to:

  • Higher triglyceride levels. Typically, the body uses insulin to move sugar from blood into cells, where it's used for energy or stored as glycogen. When you have insulin resistance, your body converts more sugar into triglycerides instead.
  • Lower HDL levels. Your body uses HDL to clear out excess triglycerides, which reduces your HDL levels. Excess blood sugar can also attach to HDL and cause it to break down more quickly than usual, lowering your HDL level.
  • Higher VLDL levels. Very low-density lipoprotein (VLDL) is a type of bad cholesterol. It's made of smaller particles than LDL. When your triglyceride levels are high, more VLDL is created.
  • When HDL is busy clearing out excess triglycerides, there's less HDL available to clear out cholesterol from your blood vessels.

    The longer they stick around in your blood vessels, the more time triglycerides, LDL, and VLDL have to stick to your artery walls. This causes your arteries to narrow and harden, which means your heart has to work harder to pump blood through your body.

    To reduce your risk for heart disease, it's important to:

  • Eat a well-balanced diet. A Mediterranean diet may have benefits for heart health. This diet is rich in fruits, vegetables, whole grains, beans, nuts, seeds, and healthy fats.
  • Get regular physical activity. Reducing sedentary time and getting more exercise may help reduce your blood pressure, cholesterol, and abdominal fat.
  • Find ways to manage stress. High levels of stress hormones can increase your blood pressure, blood pressure, and body fat levels.
  • Get enough quality sleep. This may help prevent high blood pressure and high blood sugar. It's also important for your overall well-being and energy levels.
  • Take your prescribed medications. Your doctor may prescribe medications to help manage your blood sugar, blood pressure, and cholesterol levels.
  • In some cases, your doctor may recommend other treatments or lifestyle changes to help manage type 2 diabetes and reduce your risk for heart issues.

    Several risk factors for heart disease are more likely to occur in people with type 2 diabetes.

    However, there are steps you can take to lower your risk for heart complications. Eating a healthy diet, staying active, managing stress, getting enough sleep, and taking your recommended medications can help.

    Your doctors, nurses, dietitians, and other healthcare providers can help you learn how to make lifestyle changes and get the treatment you need to protect your heart health.

    Leave a comment

    Diabetes Drugs Market | Size, Growth Rate, Key Company Share, And Global Industry Trends Forecast 2020-2026

    Mar 24, 2020 (The Expresswire) -- Diabetes Drugs Market To Expand Rapidly at Notable 21.4% CAGR as the various factors contributing to the Market growth of Diabetes Drugs over the forecast period 2020 to 2026. Report segments Diabetes Drugs Market by Type, Application, End-User and Region With Global Industry Forecast To 2026.

    The Report gives the clear picture of current scenario which includes historical and projected Diabetes Drugs Market size, Share, industry growth, trends in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report also gives a broad study of the different market segments and regions.

    Get Sample Copy of Diabetes Drugs Market 2020 Report

    Report analyzes Global Diabetes Drugs Market Growth Information By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors), Diabetes Type (Type 1, Type 2), Route of Administration (Oral, Subcutaneous, Intravenous), Distribution Channel (Online pharmacies, Hospital Pharmacies, Retail Pharmacies) and Region.

    The Global Diabetes Drugs is presumed to register a significant CAGR during the forecast period (2020-2026) owing supportive government policies.

    Diabetes Drugs Key Players Market Studied In Report:

    Some of the leading companies that are operating in the global diabetes drugs market are Novo Nordisk A/S, Sanofi, Merck and Co., Inc., Eli Lilly and Company, AstraZeneca, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Novartis AG, Johnson and Johnson Services, Inc., and Bayer AG.

    The global diabetes drug market derives growth from advancements in drug delivery systems. According to a report published by Fortune Business Insights, titled "Diabetes Drugs: Global Market Analysis, Insights and Forecast, 2019-2026," the market was valued at US$ 48,753.1 Mn in 2018. Fortune Business Insights has predicted that the market will be valued at US$ 78,261.7 Mn by the end of 2026, thereby exhibiting a CAGR of 6.1%.

    Availability of Low-Cost Insulin to Boost the Market

    Insulin is one of the most widely used drugs for the treatment of diabetes. The exceptional properties and clinical efficacy of insulin have led to a rising uptake. Despite high efficacy, the cost associated with insulin has been a barrier towards the growth of insulin. Considering this factor, many companies are exploring potential ways to the reduced cost associated with insulin for management of diabetes. In 2019, Eli Lilly and Company, launched a new insulin drug, that was almost half the price of its previous brands. Eli Lilly announced the low-cost insulin 'Lispro', a product that was priced significantly less than its previous Humalog injection. Fortune Business Insights' latest report on the global market is an encompassment of such product advancements. The report gauges the impact of product innovations, similar to Lispro, on the global market.

    Encouraged by High Demand, Glenmark Extends Insulin Sales in India

    In 2019, Glenmark Pharmaceuticals announced that it plans to bring its Remogliflozin Etabonate to India. The high demand for diabetes drugs in India has influenced Glenmark's latest move. Additionally, a huge diabetic patient pool has also contributed to the high demand for diabetes drugs in India. Such competitor moves have aided the growth of the global diabetes drugs market. The report includes company activities, similar to the aforementioned case. The report includes detailed analysis of company activities such as takeovers, mergers and acquisitions, agreements, and investment.

    Increasing Drug Approvals Have a Positive Impact on Overall Market

    The high prevalence of diabetes on a global scale has paved way for several clinical trials. Increasing drug approvals have aided the growth of the global diabetes drugs market. Novo Nordisk's 2018 launch of Ozempic and Fiasp is a perfect example of the aforementioned case. Additionally, the company received approval from the Food and Drug Administration and this has aided the business expansion of Novo Nordisk. The company's latest drug approvals will bode well for the global diabetes market and is likely to enable growth of the market in the coming years.

    Fortune Business Insights has summarized the impact of several companies on the global market. Furthermore, Fortune Business Insights has labelled out leading companies that have made significant contributions to the growth of the global diabetes drug market.

    Intended Audience:

    Diabetes Drugs Key Players

    Diabetes Drugs Suppliers

    Research and Development (RandD) Companies

    Distributer and Supplier companies

    End Users

    Consultants and Investment bankers

    Government as well as Independent Regulatory Authorities

    Report Highlights:

    In-depth information about the latest Diabetes Drugs Industry trends, opportunities, and challenges.

    Extensive analysis of the growth drivers And barriers.

    Competitive landscape consisting of investments, agreements, contracts, novel product launches, strategic collaborations, and mergers and acquisitions.

    List of the segments and the niche areas.

    Comprehensive details about the strategies that are being adopted by key players.

    Table Of Content:

    Introduction

    1.1. Research Scope

    1.2. Market Segmentation

    1.3. Research Methodology

    1.4. Definitions and Assumptions

    Executive Summary

    Market Dynamics

    3.1. Market Drivers

    3.2. Market Restraints

    3.3. Market Opportunities

    Key Insights

    Continued…

    Browse Complete Diabetes Drugs Market Report Information

    About us:

    Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

    At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

    Contact Us:

    US: +1 424 253 0390

    UK: +44 2071 939123

    APAC: +91 744 740 1245

    Press Release Distributed by The Express Wire

    To view the original version on The Express Wire visit Diabetes Drugs Market | Size, Growth Rate, Key Company Share, And Global Industry Trends Forecast 2020-2026

    COMTEX_363764389/2598/2020-03-24T06:31:40

    Leave a comment

    9 Diabetes Care Tips During the Coronavirus Pandemic

    If you've been keeping up with federal guidance on who's at higher risk for complications from COVID-19, you know that people with diabetes are among the affected groups. People older than 60, along with those who have respiratory problems, high blood pressure, and heart disease are, too, notes the Centers for Disease Control and Prevention (CDC).

    That said, if you have diabetes, the disease doesn't appear to increase your risk of being infected, according to the American Diabetes Association (ADA). This is apparently true even though research, including a review published in the Indian Journal of Endocrinology and Metabolism, shows that the immune systems of people with persistent hyperglycemia function less well. With COVID-19 — the disease caused by the coronavirus — the real problem is that people with diabetes are more vulnerable to complications and getting seriously ill from the virus once they are infected, says the ADA.

    "In China, where most cases have occurred so far, people with diabetes had much higher rates of serious complications and death than people without diabetes," the organization explains in its online guide to COVID-19. That's because people who already have diabetes-related health problems are likely to fare worse if infected simply because of those problems. A person with diabetes who is otherwise healthy doesn't carry the same level of risk.

    Furthermore, it doesn't appear to matter what type of diabetes you have. "We tell our patients with either type 1 or type 2 diabetes that as of today there is no information saying whether patients with type 1 have a higher risk in comparison with type 2, or vice versa," says Katherine Araque, MD, the director of endocrinology at the Pacific Neuroscience Institute at Providence Saint John's Health Center in Santa Monica, California.

    RELATED: The Latest News on COVID-19

    Understanding COVID-19 and Its Symptoms

    According to the World Health Organization (WHO), coronaviruses are a large family of viruses that cause diseases including the common cold, but also more severe illnesses such as Middle East respiratory syndrome (MERS); severe acute respiratory syndrome (SARS); and COVID-19, which first became known at the end of 2019 during an outbreak in the city of Wuhan in China's Hubei province and has since developed into a pandemic. As of now, there is no vaccine or cure for the coronavirus that causes COVID-19.

    Common symptoms of COVID-19 include fever, tiredness, dry cough, aches and pains, nasal congestion, runny nose, sore throat, and diarrhea, WHO reports. Some infected people have no symptoms at all, but they can still spread the virus.

    For most people the disease is mild, and about 80 percent of those infected recover from COVID-19 without needing hospitalization or special treatment. Yet around 1 out of every 5 infected people do become seriously ill, develop difficulty breathing, and require hospital care. While estimates for the death rate vary, even at a low-end estimate of 1 percent, COVID-19 is 10 times more deadly than the seasonal flu, says Anthony Fauci, MD, the director of the National Institute of Allergy and Infectious Diseases, as reported by CNBC.com.

    If you have fever, cough, and difficulty breathing, WHO advises you to seek medical attention. Stay at home and call your doctor. Don't go to an emergency room unless you are having a medical emergency, in which case you should call 911, advises the CDC. The agency describes the emergency warning signs for COVID-19 in adults as difficulty breathing or shortness of breath; persistent pain or pressure in the chest; new confusion or inability to arouse; and bluish lips or face.

    RELATED: 4 Misconceptions About the Coronavirus

    Given all that, if you have diabetes and wish to stay in the best health possible during this pandemic, Dr. Araque and other experts have some advice.

    1. Follow the CDC Guidelines for Everyone

    "We know that we should follow the CDC guidelines with regard to symptoms and when to test, regardless of the underlying diagnosis of diabetes," says Araque.

    Those guidelines include:

  • Clean your hands often with soap and hot water or sanitizer that is at least 60 percent alcohol.
  • Avoid touching your eyes, nose, and mouth with unwashed hands.
  • Avoid close contact and practice social distancing (staying at least 6 feet apart).
  • Cover coughs and sneezes with a tissue (then clean your hands!).
  • Clean and disinfect frequently touched surfaces daily, and dirty ones immediately.
  • Stay home if you're sick.
  • Separate yourself from others if you have been diagnosed with COVID-19 or think you have it.
  • Wear a face mask if you are sick.
  • Call ahead about medical attention unless you are having a medical emergency.
  • Of course, in this fast-moving pandemic, local, state, and federal regulations and guidelines are constantly shifting regarding meetings, gatherings, travel, working, and when you should stay at home. Follow the latest ones, as they are meant to slow the spread of the virus.

    RELATED: How to Manage Anxiety in the Time of COVID-19

    2. Keep Your Diabetes Treatment Supplies and Equipment Clean and Disinfected

    "We advise our patients to please keep up hygiene at home, to keep washing their hands," says Araque. "For patients with diabetes, it is important to wash their hands thoroughly before administering insulin or injectable medications." They should also use soap and water to clean the areas on their body where they inject their medications. She further cautions patients not to share needles or pens, and to dispose of needles safely.

    3. Keep Your Prescriptions Filled and Stock Up on Extra Supplies

    "We want to ensure that those patients have all their medications — not only the medications to treat diabetes but the medications to treat hypoglycemia," says Araque. She advises having extra glucagon or glucose tablets in case your blood sugar drops too low. People who take insulin should have backup insulin pens (or syringes and vials) if needed, and extra ketone strips.

    "Contact your insurer or diabetes supplier about increasing your allotment of supplies," advises Melissa Young, PharmD, CDCES, a pharmacist at University of Utah School of Medicine in Salt Lake City and a spokesperson for the Association of Diabetes Care and Education Specialists. "You do not want to run out of continuous glucose monitoring sensors or pump tubing. If your pump malfunctions, calling the manufacturer will usually be the first step. If a glucometer malfunctions, there is an 800 number on the back of the glucometer, try that first. Typically, manufacturer support is available to assist with glucometer questions."

    As for how much you should stock up on: "The CDC recommends a 14-day self-quarantine period for anyone exposed to the coronavirus, so to be safe, at least several weeks' to a month's supply of medications on hand is recommended," says Dr. Young.

    RELATED: What to Pack in Your Diabetes Emergency Bag

    4. Check for Measures That Make It Easier to Get Those Extra Supplies

    If you are worried about the possibility that your prescription coverage won't allow early refills, check with your pharmacy benefit provider or insurance provider. "Now that a national emergency has been declared, many insurers have increased allowances for [number of] days' supplies or early refills for chronic care, noncontrolled — such as nonopioid — medications for underlying medical conditions such as diabetes and high blood pressure," says Young.

    For instance, the large pharmacy benefit manager CVS Caremark announced on March 12 that it is working with its clients to waive early refill limits on 30-day prescription maintenance medications, and that furthermore, Aetna will offer 90-day maintenance medication prescriptions for insured and Medicare members.

    "Contact your regular pharmacy or diabetes supplier as soon as possible," Young advises. "Your prescription information is on file, and they are aware of your insurance plan allowances on medications and supplies to be received per prescription." Call the toll-free number on the back of your health insurance card for benefit details, she says. Take advantage of mail-order delivery if you are instructed to stay at home or are taking self-isolation measures.

    If you are worried about the cost of extra medication and lack adequate coverage, check the JDRF resource page for help with diabetes medication costs. JDRF is a nonprofit dedicated to type 1 diabetes advocacy and research.

    RELATED: What to Do if You Can't Afford Your Insulin

    5. Don't Worry Yet About the Medication or Insulin Supply Chain

    You may be wondering if measures to slow the spread of the coronavirus behind COVID-19 will affect your ability to get your medications and medical supplies on time. As of Monday, March 16, 2020, per an email ADA sent to Everyday Health, the organization was unaware of any interruptions or issues with the supply chain of insulin, but that the situation is changeable.

    As of Tuesday, March 17, 2020, a web page on type 1 diabetes and COVID-19 published by the JDRF stated that they are in touch with drug and diabetes supply manufacturers and also are unaware of any disruptions. "These manufacturers have communicated to us that COVID-19 is not having an impact on their current manufacturing and distribution capabilities. We will continue to monitor the situation and update the type 1 diabetes community should anything change," says the organization. The page links out to statements by several major manufacturers who say they don't foresee any supply shortages or disruptions. The JDRF advises people to keep checking this page for the latest developments.

    RELATED: What to Know Before You Use OTC Insulin

    6. Know That Some Over-the-Counter Medications Can Affect Blood Glucose

    Some over-the-counter medications used to treat cold and flu symptoms may affect your blood sugar levels, the JDRF warns. These include:

  • Cough syrups, except those that are labeled sugar-free
  • Pills that contain the same ingredients as syrups and do not have carbohydrates
  • Decongestants such as phenylephrine and pseudoephedrine
  • Aspirin in large doses
  • Advil (ibuprofen), which can increase the hypoglycemic effect of insulin
  • Ask your healthcare provider if you are not sure about the effects of an over-the-counter medication.

    RELATED: 7 Common Meds That Can Make It Harder to Manage Your Blood Sugar

    7. Be Vigilant for Signs of DKA, Especially if Insulin or Other Medications Run Low

    People with type 1 diabetes, and, in rare cases, long-standing type 2 diabetes, are vulnerable to developing a potentially life-threatening condition known as diabetic ketoacidosis (DKA), notes Araque. When the body doesn't have enough insulin to convert glucose into energy, it begins to break down fat to use as fuel. The result is a buildup of acids in the bloodstream known as ketones.

    "We advise patients to check their ketones at home if they are experiencing persistent hyperglycemia to make sure they don't go into DKA, regardless of whether they have any symptoms. This can happen in patients that miss injections or that have failures in their pumps or any problems getting access to insulin. They need to go to the hospital, separate of any symptoms of COVID-19."

    8. Maintain a Healthy Lifestyle by Prioritizing Diet, Exercise, and Sleep

    With gyms closed and many sports activities postponed, it can be a challenge to stay on the healthy regimen you established before the pandemic. "In my experience, some patients become sedentary when they stay at home," notes Araque. If you are not under quarantine or otherwise advised to stay at home, go for a walk outside in the park (while maintaining social distancing guidelines). If you are homebound, pop in an exercise video or hit the Peloton. Also make sure you are stocking up on food that helps you consume carbohydrates in a healthy way, the JDRF advises. Also, continue to manage stress and prioritize sleep — two other essentials for managing your blood sugar.

    RELATED: 8 Healthy Carbs for People With Type 2 Diabetes

    9. If You Call the Doctor, Keep Both COVID-19 and Diabetes in Mind

    "When people with diabetes call their doctor's office for advice, they should be prepared to report blood sugar values, medication doses taken or missed, severity of respiratory symptoms, any nausea or vomiting, and how much they are able to eat or drink," says Julie Adkison, PharmD, CDCES, a pharmacist and certified diabetes educator in Houston, who runs the blog My Diabetes Village. "Be aware of the signs and symptoms of DKA so that you know when to check for ketones, and seek care immediately if needed."

    And don't be afraid to voice your concerns to your healthcare team. "This is not the time to not ask questions," says Araque. "This is the time to ask questions and call your provider. It's better to ask them than to delay care."

    Leave a comment

    CIS cooperation in diabetes prevention and treatment discussed in Minsk

    An archive photo

    An archive photo

    MINSK, 18 March (BelTA) – A meeting of a group of experts to finalize the draft CIS program of cooperation in prevention and treatment of diabetes for 2021-2025 is held in the CIS headquarters in Minsk, BelTA has learned from the press service of the CIS.

    The document was developed by the CIS Expert Council on diabetes issues with the participation of representatives of Armenia, Belarus, Kazakhstan, Moldova, Azerbaijan, Russia, Tajikistan, CIS Interparliamentary Assembly and the WHO Regional Office. Among the major aims of the draft program is the consistent implementation of the provisions of the UN General Assembly resolution of 20 December 2006 on diabetes. The draft program also aims to unite efforts of the CIS countries in the implementation of the UN Sustainable Development Goals and the Global Action Plan for the Prevention and Control of Noncommunicable Diseases (NCDs) 2013-2020. Plans are in place to reduce premature mortality from non-communicable diseases by a third by 2030. The capacities of the CIS countries, the economic features and the statistics indicators of the diabetes situation were also taken into account as the document was drawn up.

    The major activities of the program are focused on the early diabetes detection, effective treatment using advanced diagnostics, the introduction of the up-to-date medical technologies and the guarantees of providing the high-quality insulin, the means of insulin administration, the tableted antihyperglycemic medicine and self-control means to patients. Plans are in place to improve diabetes prevention methods and carry out sanitary and educational work among people and to raise the professional knowledge of medical workers of primary outpatient healthcare institutions on early diabetes detection, adequate diagnostics, effective treatment and monitoring of patients with diabetes.

    The draft program was approved at a session of the CIS Healthcare Cooperation Council in Dushanbe in November 2019. After the final document approval, it will be submitted to the CIS Heads of Government Council in accordance with the established procedure.

    Leave a comment

    Mathematical Model can Lead to Better Diabetes Treatment

    MIT researchers have now developed a mathematical model that can predict the behavior of different kinds of GRIs in both humans and in rodents. They believe this model could be used to design GRIs that are more likely to be effective in humans and to avoid drug designs less likely to succeed in costly clinical trials.

    'One promising new strategy to treat diabetes is to give patients insulin that circulates in their bloodstream, staying dormant until activated by rising blood sugar levels. '

    "There are GRIs that will fail in humans but will show success in animals, and our models can predict this," says Michael Strano, the Carbon P. Dubbs Professor of Chemical Engineering at MIT. "In theory, for the animal system that diabetes researchers typically employ, we can immediately predict how the results will translate to humans."

    Strano is the senior author of the study, which appears today in the journal Diabetes. MIT graduate student Jing Fan Yang is the lead author of the paper. Other MIT authors include postdoc Xun Gong and graduate student Naveed Bakh. Michael Weiss, a professor of biochemistry and molecular biology at Indiana University School of Medicine, and Kelley Carr, Nelson Phillips, Faramarz Ismail-Beigi of Case Western Reserve University are also authors of the paper.

    Optimal design

    Patients with diabetes typically have to measure their blood sugar throughout the day and inject themselves with insulin when their blood sugar gets too high. As a pote ntial alternative, many diabetes researchers are now working to develop glucose-responsive insulin, which could be injected just once a day and would spring into action whenever blood sugar levels rise.

    Scientists have used a variety of strategies to design such drugs. For instance, insulin might be carried by a polymer particle that dissolves when glucose is present, releasing the drug. Or, insulin could be modified with molecules that can bind to glucose and trigger insulin activation. In this paper, the MIT team focused on a GRI that is coated with molecules called PBA, which can bind to glucose and activate the insulin.

    The new study builds on a mathematical model that Strano's lab first developed in 2017. The model is essentially a set of equations that describes how glucose and insulin behave in different compartments of the human body, such as blood vessels, muscle, and fatty tissue. This model can predict how a given GRI will affect blood sugar in different parts of the body, based on chemical features such as how tightly it binds to glucose and how rapidly the insulin is activated.

    "For any glucose-responsive insulin, we can turn it into mathematical equations, and then we can insert that into our model and make very clear predictions about how it will perform in humans," Strano says.

    Although this model offered helpful guidance in developing GRIs, the researchers realized that it would be much more useful if it could also work on data from tests in animals. They decided to adopt the model so that it could predict how rodents, whose endocrine and metabolic responses are very different from those of humans, would respond to GRIs.

    "A lot of experimental work is done in rodents, but it's known that there are lots of imperfections with using rodents. Some are now quite wittily referring to this situation as 'lost in [clinical] translation,'" Yang says.

    "This paper is pioneering in that we've taken our model of the human endocrine system and we've linked it to an animal model," adds Strano.

    To achieve that, the researchers determined the most important differences between humans and rodents in how they process glucose and insulin, which allowed them to adapt the model to interpret data from rodents.

    Using these two variants of the model, the researchers were able to predict the GRI features that would be needed for the PBA-modified GRI to work well in humans and rodents. They found that about 13 percent of the possible GRIs would work well in both rodents and humans, while 14 percent were predicted to work in humans but not rodents, and 12 percent would work in rodents but not humans.

    "We used our model to test every point in the range of potential candidates," Gong says. "There exists an optimal design, and we found where that optimal design overlaps between humans and rodents."

    Analyzing failure

    This model can also be adapted to predict the behavior of other types of GRIs. To demonstrate that, the researchers created equations that represent the chemical features of glucose-responsive insulin that Merck tested from 2014 to 2016, which ultimately did not succeed in patients. They now plan to test whether their model would have predicted the drug's failure.

    "That trial was based on a lot of promising animal data, but when it got to humans, it failed. The question is whether this failure could have been prevented," Strano says. "We've already turned it into a mathematical representation, and now our tool can try to figure out why it failed."

    Strano's lab is also collaborating with Weiss to design and test new GRIs based on the results from the model. Doing this type of modeling during the drug development stage could help to reduce the number of animal experiments needed to test many possible variants of a proposed GRI.

    This kind of model, which the researchers are making available to anyone who wants to use it, could also be app lied to other medicines designed to respond to conditions within a patient's body.

    "You can envision new kinds of medicines, one day, that will go in the body and modulate their potency as needed based on the real-time patient response," Strano says. "If we get GRIs to work, this could be a model for the pharmaceutical industry, where a drug is delivered, and its potency is constantly modulated in response to some therapeutic endpoint, such as levels of cholesterol or fibrinogen."

    Source: Eurekalert

    Leave a comment

    FDA rejects lower-dose empagliflozin 2.5 mg for type 1 diabetes

    The FDA on Friday issued a complete response letter for a supplemental new drug application for a 2.5 mg dose of the SGLT2 inhibitor empagliflozin as an adjunct to insulin for adults with type 1 diabetes, according to a press release from Boehringer Ingelheim and Eli Lilly.

    The FDA issues a complete response letter to an applicant if the agency determines that it will not approve the application or abbreviated application in its present form for one or more reasons. As Healio previously reported, the FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 14-2 in November against recommending approval of a supplemental NDA for empagliflozin 2.5 mg as an oral medication adjunct to insulin therapy for adults with type 1 diabetes. Committee members cited uncertainty regarding the adjudication of diabetic ketoacidosis (DKA) and a lack of adequate data to support evidence for safety and efficacy.

    The proposed dose is lower than currently approved 10 mg and 25 mg doses of empagliflozin (Jardiance) for type 2 diabetes.

    "The challenges of managing blood sugar levels for those with type 1 diabetes, and the desire for new treatment options, reveal important unmet needs in the diabetes community," Mohamed Eid, MD, MPH, MHA, vice president of clinical development and medical affairs, cardio-metabolism and respiratory medicine at Boehringer Ingelheim, said in the release. "We remain committed to the continued study of therapies that may improve outcomes for adults with cardiorenal metabolic conditions, including diabetes."

    U.S. Food and Drug Administration 

    The FDA on Friday issued a complete response letter for a supplemental new drug application for a 2.5 mg dose of the SGLT2 inhibitor empagliflozin as an adjunct to insulin for adults with type 1 diabetes, according to a press release.

    Source: FDA

    Insulin and pramlintide (Symlin, AstraZeneca) are the only drugs currently approved for the treatment of type 1 diabetes in the United States, and other noninsulin therapies have met similar hurdles with the FDA. In March 2019, the FDA issued a complete response letter regarding an NDA for oral sotagliflozin (Zynquista, Sanofi and Lexicon), a first-in-class dual SGLT1 and SGLT2 inhibitor for adults with type 1 diabetes, also citing a potential increased risk for DKA. – by Regina Schaffer

    Disclosure: Eid is vice president of clinical development and medical affairs, cardio-metabolism and respiratory medicine at Boehringer Ingelheim.

    Leave a comment

    US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes

    RIDGEFIELD, Conn. and INDIANAPOLIS, March 20, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has issued a complete response letter for the supplemental New Drug Application (sNDA) of the investigational medicine empagliflozin 2.5 mg as an adjunct to insulin for adults with type 1 diabetes. Empagliflozin 2.5 mg is being developed by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY).

    The letter indicates that the FDA is unable to approve the application in its current form, consistent with the outcome of the Endocrinologic and Metabolic Drugs Advisory Committee in November.

    "The challenges of managing blood sugar levels for those with type 1 diabetes, and the desire for new treatment options, reveal important unmet needs in the diabetes community," said Mohamed Eid, M.D., M.P.H., M.H.A., vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc. "We remain committed to the continued study of therapies that may improve outcomes for adults with cardiorenal metabolic conditions, including diabetes."

    About Diabetes Approximately 34.2 million Americans and an estimated 463 million adults worldwide have type 1 and type 2 diabetes. Type 2 diabetes is the most common form, accounting for an estimated 90 to 95 percent of all diagnosed adult diabetes cases in the U.S. Diabetes is a chronic condition that occurs when the body does not properly produce, or use, the hormone insulin.

    Boehringer Ingelheim and Eli Lilly and Company

    In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance that centers on compounds representing several of the largest diabetes treatment classes. Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributing to the alliance. The alliance leverages the strengths of two of the world's leading pharmaceutical companies to focus on patient needs. By joining forces, the companies demonstrate their commitment, not only to the care of people with diabetes, but also to investigating the potential to address areas of unmet medical need. Clinical trials have been initiated to evaluate the impact of empagliflozin on people living with heart failure or chronic kidney disease.

    About Boehringer Ingelheim Pharmaceuticals, Inc.Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, Conn., is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.

    Boehringer Ingelheim is one of the world's top 20 pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with approximately 50,000 employees. Since its founding in 1885, the company has remained family-owned, and today our goal is to improve the lives of humans and animals through its three business areas: human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.

    Boehringer Ingelheim concentrates on developing innovative therapies that can improve and extend patients' lives. As a research-driven pharmaceutical company, it plans in generations for long-term success. Its research efforts are focused on diseases with high, unmet medical need. In animal health, the company stands for advanced prevention.

    In 2018, Boehringer Ingelheim achieved net sales of around $20.7 billion (17.5 billion euros). R&D expenditure of almost $3.7 billion (3.2 billion euros) corresponded to 18.1 percent of net sales.

    Boehringer Ingelheim is committed to improving lives and strengthening our communities. Please visit www.boehringer-ingelheim.us/csr to learn more about Corporate Social Responsibility initiatives.

    For more information, please visit www.boehringer-ingelheim.us, or follow us on Twitter @BoehringerUS.

    About Lilly Diabetes Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a wide range of therapies and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com.

    About Eli Lilly and CompanyLilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels. 

    This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about empagliflozin as a potential treatment for type 1 diabetes and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date or that empagliflozin will receive additional regulatory approvals. For a further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, please see Lilly's most recent Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

    P-LLY

    MPR-US-101140

    CONTACT:  Jennifer Forsyth  Director, Public Relations  Boehringer Ingelheim Pharmaceuticals, Inc.  Email: [email protected]   Phone: (203) 791-5889

    Stephan Thalen Global Business Communications Lilly Diabetes and Lilly USA Email: [email protected]  Phone: (317) 903-5640

    SOURCE Eli Lilly and Company

    Related Links

    http://www.lilly.com

    Leave a comment

    Adam Brown: ‘Why I Decided to Become a Diabetes Mental Health Professional’

    It's no secret that people with diabetes are prone to depression and mental health issues, but historically these issues have been categorically ignored.

    Even now in 2020, the psychosocial aspects of life with diabetes are not adequately addressed by healthcare professionals, and/or many patients don't feel comfortable asking for help even when they need it most. Or help is just too hard to come by.

    All of this is why longtime type 1 Adam Brown, well known by many in the diabetes community for his technology-focused work at diaTribe and Close Concerns over the past decade, is pivoting his career to become a mental health provider for people with diabetes.

    As he pursues his new degree and licensing, Adam is staying involved in diabetes technology through part-time work with Tidepool, the nonprofit now building a next-generation automated insulin delivery system known as Tidepool Loop.

    We talked with Adam recently about his experience and why he's decided to devote himself to addressing mental health for people with diabetes.

    DM: Hey Adam, let's start with what you've observed about how mental health care is currently working (or not) for people with diabetes?

    One thing that has surprised me is the difference in "dosage." A standard appointment in mental health is 50 minutes long. Brief therapy might be six or 10 or 12 sessions. So if you get 50 minutes each session, that might be 10 hours of face-to-face time in "brief" therapy. But in the diabetes world, to get that amount of time with a healthcare provider might take ten years! That's a staggering difference — even in brief therapy, clients get much more one-on-one attention compared to what we get in diabetes.

    The trade off to that is access; if a therapist is meeting with people for 50 minutes at a time, they might be able to see 25 or 30 clients a week at the max. That means any one provider can't reach too many people at one time. I'm really interested in exploring how we can scale mental health treatment in a way that maintains the personal touch, but also lets you reach more people.

    Yes! Another nuance is insurance and how it often doesn't cover mental health very well. For a healthcare provider, there is a process to getting on an insurance panel, and it may add some administrative burden to make insurance claims. For some therapists, the only way to make it work financially is to focus on cash-pay (i.e., non-insurance), which ends up meaning that a lot of people can't afford the care. And yet, so many people could benefit from mental healthcare!

    We need to figure out how to get it into their hands. In some ways, it's a strange situation, where everyone agrees that mental health is so super important and that therapy is helpful, but not enough people have access to it. We must do better!

    What does the study path look like for becoming a mental health professional?

    You need to get licensed first as a clinician in your state. I'm doing a two-year master's in counseling psychology. That allows me to get one of two licenses:

  • Licensed Marriage and Family Therapist (LMFT) provides general counseling on social issues for individuals, couples or families.
  • Licensed Professional Clinical Counselor (LPCC) focuses on treatment and counseling for those with mental health and substance abuse issues. This credential is actually more common outside of California.
  • In addition to school, you must accrue a total of 3,000 clinical hours to be licensed in California. From where I sit now — six months in — it will still be a couple years until I get licensed and can see patients on my own.

    I'm also doing a weekend program — which is its own level of insanity — in part because school is expensive and it's nice to have an income while I'm studying. It's one night per week, and then once a month I have a class over three days stretching over 20 hours. We basically cover half a semester in one weekend. I love it but it is a full load!

    Did you always aspire to become a healthcare provider?

    Yes, I do think it's always been kicking around in my mind. Working in diabetes, I've always been interested in behaviors and mental health. And I have always thought it would be awesome to be a healthcare provider, as it would be something I would really enjoy.

    What was a real turning point for me came about 18 months ago, when I experienced and then wrote about having my appendix rupture. When I was sitting in the hospital recovering, away from the grind of everything, I found myself wondering where I wanted to be in a few years. Quickly after that, I started interviewing diabetes psychologists about their advice on going in this direction. They were all supportive and strongly encouraged me!

    Is there a special credential for mental health experts focusing on diabetes? Let's back up for a moment to how you got here. Can you share your personal diabetes journey?

    I was diagnosed at 12 and had a somewhat typical teenage experience. I did my best on fingersticks and injections. As the oldest of six kids, I took on most of my own care immediately.

    That colors my views and comes back full circle later on how I approach diabetes. Like many teens, I maintained an A1C in the 8 to 9 percent range, only filled out my logbooks right before a doctor's appointment, and wasn't that diligent about data because it was so burdensome. In college, a few turning points happened:

  • A roommate was a bodybuilder and intensely disciplined, so that had an impact on me becoming more methodical about exercise and nutrition.
  • I took a bunch of nutrition classes in college, which I think gave me an appreciation for what a powerful diabetes tool that food can be.
  • I started as an intern at diaTribe in my junior year of college, got introduced to this whole industry, began going to conferences and writing about diabetes.
  • It was at a conference during my summer internship that I first heard about continuous glucose monitoring (CGM). I was so impressed, that I went to the lobby of the hotel after a panel discussion and called Dexcom to order the (then-newest) Seven Plus model. I've been wearing a CGM ever since. That was so transformative for me. I'm a geek about these sorts of things, because I enjoyed numbers and data and taking a more quantified self-approach to diabetes. It helped me figure out what worked for me.
  • Those all helped turn things around for me and made managing diabetes easier for me.

    Tell us about your decade of work with Close Concerns/diaTribe?

    At the time I joined as a summer intern, helping contribute to diaTribe and Close Concerns. I joined Close Concerns full-time in 2011 after graduating from college.

    I was lucky to be in Close Concerns' two-year associate's program, and then stayed on and led diabetes technology writing through the end of 2019. What a marvelous journey it was!

    My role at diaTribe grew to editing each issue, writing my own column, Adam's Corner, and eventually publishing a book.

    Do any highlights come to mind?

    There are so many highlights! Some that stand out are:

  • Covering all-things diabetes technology from 2010 to 2019 — moving from blood glucose meters to CGM, from manual to more automated insulin dosing, from locked-down medical devices to smartphone apps, from cables to wireless, etc.! At so many points, things seemed impossible (e.g., CGM data on a smartphone app) until they became possible and then the standard.
  • Advocating at the Food and Drug Administration (FDA) to get CGM approved for insulin dosing — ultimately paving the way for Medicare coverage of CGM! People still tell me they remember the plane analogy presentation I shared.
  • Accelerating the Beyond A1C movement with many presentations and articles over the past few years (e.g., here and here), along with continuously advocating at the FDA for recognition of time in range (TIR).
  • Getting to meet people with diabetes at conferences like ADA, AADE, Friends for Life, the DiabetesMine Innovation forums, local JDRF events, and beyond! It has been such a joy and privilege to spend time with so many amazing people who are so committed to improving life with diabetes.
  • Did that work pave the way toward a career shift?

    Yes, it did. I actually feel what's underneath all of those things is mental health. Overall, what is the context of your life in terms of the tools we apply to diabetes management? Mental health is a lot about understanding context in people's lives — everything from how you were parented growing up, to the community you live in now and what you can afford and access.

    Most of the first part of my career in diabetes was understanding the tools. Now, I'm learning to understand the context behind all of that and how to apply it to life with diabetes.

    How does this tie back in to all the new diabetes technology coming out?

    One of the big picture views I've been thinking a lot about is the nuanced difference between tools and context. The diabetes field is really good about developing tools and talking about how we make them better. But because understanding the context of every person's life takes a lot of time and is more difficult to design for, and there's not a lot of clinical time spent trying to understand all those factors.

    In the first part of my career, I got really good at going to these conferences and looking at the technology, products, and data. I also felt there was an "echo chamber" or "bubble" type of effect happening — too much focus on tools, too many opinions from the same people, and not nearly enough focus on the contextual aspects that are really important in understanding people's lives with diabetes. Everything from race, socioeconomic class, trauma history, family, community, and so much more that we must better understand better to help people with diabetes.

    Why do you think therapy has so much potential to help?

    In my application to get into school, I wrote about how I've been lucky to reach the diabetes community at scale. Writing and presenting is an amazing way to talk to many people at once — but it's often a one-way communication. In this next phase, I'm trying to learn best practices for helping people one-to-one or in a small group setting — and to have that flow of conversation and build a relationship between two people. I think both skill sets are important.

    In the therapy world, there are a lot of tools for dealing with thought patterns, stress and strong emotions, coping with unpredictability, family communication, and beyond. So much of it applies to diabetes!

    Behavior change is such a key component of mental health in the diabetes space, isn't it?

    Yes, an important piece is how you help people change, understand patterns, and get insight into ourselves.

    I tend to look at CGM as a behavior change tool, probably more than many people do. It's a decision-making aid. Mental health and psychotherapy have a lot to say about how you help people change who might be struggling. I wanted to learn more about that, and ultimately be able to be a healthcare provider in that area one day. This seemed like the best route to do so.

    Have you had to dig into your own headspace much, starting out in mental health?

    Yes, part of becoming a therapist is that you also have to cross into your own life and baggage, the things that have happened to you and looking at your own responses to things. My program strongly recommends that all of us be in therapy ourselves.

    And a lot of the program is about understanding where you come from and what makes you uncomfortable, and working through that to help clients as much as possible.

    And on the side, you're helping develop new automated insulin delivery (AID) technology?

    Yes, I am also helping Tidepool on their future Tidepool Loop project. I'm part-time there and working on Market Access, as in: How do we get Tidepool Loop into as many hands as possible?

    I believe Tidepool is unique in how it's building on the work of the DIY (do it yourself) and #WeAreNotWaiting community — let's take this amazing thing that has helped several thousand people and get it through the FDA to help even more people. That involves working with in-warranty diabetes devices, so people can be using devices we're familiar with and that are supported.

    I have been Looping for a while myself and love it. What I love even more is this interoperable vision — all these different devices working together through one app!

    Let's not forget that you're also an accomplished author of the popular diabetes book, 'Bright Spots and Landmines.' What has the reaction to that been like?

    It has been powerful and moving in so many ways. I've heard thousands of stories through emails, reviews, and in-person conversations — they are inspiring, surprising, joyous, emotional, and (sometimes) even infuriating. We've heard about 1 percent to 3 percent A1C reductions, hours more time in range per day, 20+ pounds of weight loss, reductions in medication, massive improvements in stress and diabetes outlook, and more. I still cannot believe it. I'm also incredibly proud that we made the book available for free in PDF and audiobook forms, because cost should not be a barrier to learning.

    To this day, I remain completely wowed when someone says, "Your book changed my life." I often reply, "Really?! What did you find useful?" Then, I often get to hear their diabetes story with all its twists and turns. This is why I love reading emails from readers — they remind me of the impact, but they are also incredible teachers. We might share a diagnosis and benefit from similar tips, but our lives are complicated and diverse and ever-changing.

    From an 18-month-old to an 86-year-old, no one diabetes is exactly the same, in my opinion. Even with the book reaching so many people, I still feel like I have a lot to learn!

    Thanks so much for taking the time to chat, Adam. We are so proud of you, and excited to witness your new path. Make sure to also read Adam's "goodbye column" over at diaTribe.

    Leave a comment
    Powered by Blogger.

    Search

    Swedish Greys - a WordPress theme from Nordic Themepark. Converted by LiteThemes.com.